首页 | 本学科首页   官方微博 | 高级检索  
     

磷酸二甲啡烷片在中国健康志愿者中的药物代谢动力学研究
引用本文:谭鸿毅,阳国平,黄路,杨柳,郭成贤,华烨,黄洁,陈军,刘世坤,裴奇. 磷酸二甲啡烷片在中国健康志愿者中的药物代谢动力学研究[J]. 中南药学, 2014, 0(5): 423-427
作者姓名:谭鸿毅  阳国平  黄路  杨柳  郭成贤  华烨  黄洁  陈军  刘世坤  裴奇
作者单位:[1]中南大学药学院,长沙410013 [2]中南大学湘雅三医院,长沙410013
基金项目:国家自然科学基金(No.81302851;No.81373476;No.81301924); 湖南省卫生厅科研基金课题(No.132013-028); 重大疾病新药临床评价研究综合技术平台建设(No.2012ZX09303014-001)
摘    要:
目的研究磷酸二甲啡烷片在中国健康志愿者中单次和连续多次给药药动学特征。方法 12例受试者随机开放3×3拉丁方试验设计,研究单次给药和连续多次给药药动学特征。采用HPLC-MS/MS法测定血浆中二甲啡烷的药物浓度。药动学参数采用WinNonLin软件计算。结果单次口服(10、20、40 mg)磷酸二甲啡烷片后,二甲啡烷主要药动学参数:Cmax为(1.08±0.84)、(2.16±1.64)、(4.34±2.92)μg·L-1,tmax为(2.6±1.2)、(2.8±0.9)、(2.3±0.7)h,AUClast为(13.05±12.39)、(27.02±24.86)、(54.19±46.19)μg·h·L-1,AUCinf为(14.21±13.37)、(29.32±27.15)、(58.41±51.57)μg·h·L-1,t1/2为(9.23±3.56)、(10.94±2.73)、(11.21±2.51)h。多次给药20 mg后二甲啡烷主要药动学参数:Cmax为(5.22±4.28)μg·L-1,tmax为(2.5±1.3)h,AUClast为(75.82±74.39)μg·h·L-1,AUCinf为(82.37±82.21)μg·h·L-1,t1/2为(12.02±2.47)h。结论单次给药二甲啡烷的体内过程符合一级线性动力学过程;多次给药二甲啡烷的蓄积因子接近3,符合线性累加。

关 键 词:二甲啡烷  健康志愿者  药物代谢动力学  HPLC-MS/MS法

Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers
TAN Hong-yi,YANG Guo-ping,HUANG Lu,YANG Liu,GUO Cheng-xian,HUA Ye,HUANG Jie,CHEN Jun,LIU Shi-kun,PEI Qi. Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers[J]. Central South Pharmacy, 2014, 0(5): 423-427
Authors:TAN Hong-yi  YANG Guo-ping  HUANG Lu  YANG Liu  GUO Cheng-xian  HUA Ye  HUANG Jie  CHEN Jun  LIU Shi-kun  PEI Qi
Affiliation:1. School of Pharmaceutical Sciences, Central South University, Changsha 410013; 2. Department of Pharmacy, Third Xiangya Hospital, Central South University, Changsha 410013)
Abstract:
Objective To investigate the pharmacokinetics of dimemorfan phosphate tablets at single doses or multiple doses in healthy Chinese volunteers. Methods Single oral doses of dimemorfan phosphate tablets (10, 20, and 40 mg) were given to 12 healthy volunteers (half male and half female) according to an open, random 3 × 3 latin design and received multiple doses. The concentrations of dimemorfan in plasma were determined by high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) and the pharmacokinetic parameters were calculated using WinNonlin program. Results The main pharmacokinetic parameters of dimemorfan after single doses dimemorfan phosphate tablets (10, 20 and 40 mg) were as follows: CmaX was (1.08 ±0.84), (2.16± 1.64) and (4.34±2.92) μg · L^-1, tmax was (2.6±1.2), (2.8±0.9) and (2.3 ±0.7) h, AUClast was (13.05 v 12.39), (27.02 ±24.86) and (54.19±46.19) μg ·h· L^-1, AUCinf was (14.21± 13.37), (29.32±27.15) and (58.41 ±51.57) μg ·h· L^-1, t1/2 was (9.23±3.56), (10.94±2.73) and (11.21 ±2.51) h. The parameters of dimemorfan after multiple doses (20 mg) were as follows: Cmax was (5.22±4.28) μg · L^-1, tmax was (2.5±1.3) h, AUClastWas (75.82±74.39) μg ·h· L^-1, AUCinfWas (82.37±82.21) μg ·h· L^-1, t1/2 was 02.02±2.47) h. Conclusion After 10 - 40 mg single doses ad- ministration, the pharmacokinetic results show that dimemorfan exhibits first order kinetic characteristics. After 20 mg multiple doses administration, the accumulation factor value is nearly 3 and dimemorfan shows a linear accumulation. Key words: dimemorfan; healthy volunteer; pharmacokinetics; HPLC-MS/MS
Keywords:dimemorfan  healthy volunteer  pharmacokinetics  HPLC-MS/MS
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号